Treatment of the lymphoid blast crisis of chronic myeloid leukemia

Abstract Ten patients with lymphoid-type blast crisis of chronic myeloid leukemia were treated with combination chemotherapy comprising doxorubicin, vincristine, l -asparaginase, and prednisone. Once remission was achieved in 9 (90%) , consolidation with doxorubicin, vincristine and cyclophosphamide was given, and then maintenance chemotherapy with 6 -mercaptopurine and methotrexate. Median remission duration was 12 months (range 2–18 ) and survival 17 (range 3–29 ). Drug-related toxicity was manageable, leading to a major schedule alteration in 3 cases. These data suggest that combination chemotherapy including doxorubicin improves the prognosis of lymphoid blast crisis in chronic myeloid leukemia.